Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Periodontitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Periodontitis - Pipeline Review, H1 2016', provides an overview of the Periodontitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Periodontitis - The report reviews pipeline therapeutics for Periodontitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Periodontitis therapeutics and enlists all their major and minor projects - The report assesses Periodontitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Periodontitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Periodontitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Periodontitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Periodontitis Overview 8 Therapeutics Development 9 Pipeline Products for Periodontitis - Overview 9 Pipeline Products for Periodontitis - Comparative Analysis 10 Periodontitis - Therapeutics under Development by Companies 11 Periodontitis - Therapeutics under Investigation by Universities/Institutes 12 Periodontitis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Periodontitis - Products under Development by Companies 17 Periodontitis - Products under Investigation by Universities/Institutes 18 Periodontitis - Companies Involved in Therapeutics Development 19 Amyndas Pharmaceuticals LLC 19 Caladrius Biosciences, Inc. 20 CSL Limited 21 Ensol Biosciences Inc. 22 Enzo Biochem, Inc. 23 Geistlich Pharma AG 24 Kaken Pharmaceutical Co., Ltd. 25 TGV-Laboratories 26 Periodontitis - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 AMY-101 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Drug to Antagonize C5aR for Periodontitis - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Enzo-D58 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 GM-0111 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Hesed-3000 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Mul-1867 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 PODCRC-OHS - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Recombinant Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules for Periodontitis - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Stem Cell Therapy for Osteoporosis and Periodontitis - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 taurolidine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 trafermin - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Periodontitis - Recent Pipeline Updates 52 Periodontitis - Dormant Projects 54 Periodontitis - Discontinued Products 55 Periodontitis - Product Development Milestones 56 Featured News & Press Releases 56 Oct 01, 2015: Kaken Submits a New Drug Application for "KCB-1D", Medicinal Product for Periodontal Regeneration 56 May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment 56 Nov 20, 2012: NeoStem Receives Notification Of $1.2m NIH Grant Award For First Clinical Study Of VSEL Technology In Humans 57 Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 58 Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for Periodontitis, H1 2016 9 Number of Products under Development for Periodontitis - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Comparative Analysis by Unknown Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H1 2016 19 Periodontitis - Pipeline by Caladrius Biosciences, Inc. , H1 2016 20 Periodontitis - Pipeline by CSL Limited, H1 2016 21 Periodontitis - Pipeline by Ensol Biosciences Inc., H1 2016 22 Periodontitis - Pipeline by Enzo Biochem, Inc., H1 2016 23 Periodontitis - Pipeline by Geistlich Pharma AG, H1 2016 24 Periodontitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 25 Periodontitis - Pipeline by TGV-Laboratories, H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanism of Action, H1 2016 31 Number of Products by Stage and Route of Administration, H1 2016 33 Number of Products by Stage and Molecule Type, H1 2016 35 Periodontitis Therapeutics - Recent Pipeline Updates, H1 2016 52 Periodontitis - Dormant Projects, H1 2016 54 Periodontitis - Discontinued Products, H1 2016 55
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
